CTLA4 and non-small cell lung carcinoma: The findings showed that this combined therapy in non-small cell lung cancer (NSCLC) is well tolerated when compared to CTLA4 with PD-L1 combined therapy, and that it improves responses and PFS in PD-L1–immune sensitive patients (202–205).